Reports Q3 revenue $0.9M vs. $1.4M last year.”The public markets are not yet reflecting the true value of ProPhase or the multi-year opportunities now in front of us,” said Ted Karkus, CEO and Chairman. “With Crown Medical recoveries underway, a validated and commercially ready cancer test with significant market potential, and a restructured, profitable genomics business, we see a clear path to value creation that we believe far exceeds our current share price.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRPH:
- ProPhase Labs urges shareholders to vote ‘FOR’ all proposed resolutions
- ProPhase Labs Delays Q3 Filing Amid Reorganization
- ProPhase Labs announces publication of BE-Smart Esophageal Cancer study
- ProPhase Labs engages RedChip to lead investor relations efforts
- ProPhase Labs announces study validating BE-Smart cancer test